Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Such factors include, but are not limited to, the Company's ability to achieve business and strategic objectives, increase sales and acceptance of products, adoption by CMS of a new payment model, and that such model will prove beneficial to the Company, which is not assured, implement expansion plans, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, ability to successfully defend itself in litigation matters, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company the effects of a global pandemic, and other risks detailed in the Company's filings with the Securities and Exchange Commission.
Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For example, when the Company discusses the potential of ProFound AI® Risk, the benefits of the Company's products, the Enterprise sales cycle, trends driving positive shifts, and clinical plans and updates, it is using forward-looking statements.
For more information, visit "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995Ĭertain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
0 kommentar(er)
